Shares of Organon (OGN) surged sharply today after reports that Sun Pharmaceutical Industries may be preparing a potential bid for the company. According to the Economic Times, Sun Pharma (IN:SUNPHARMA) is moving ahead with a binding offer of around $12 billion. While details are still limited, the news has fueled takeover speculation, sending OGN stock up about 26% at the market open on Friday.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Later on, Sun Pharmaceutical issued a statement, stating the report is “speculative” and that there is no material update to disclose at this time. The company added that it will inform exchanges if anything significant develops.
For context, Organon is a healthcare company focused on women’s health, biosimilars, and established medicines. It was spun off from Merck & Co. (MRK) in 2021. Meanwhile, India-based Sun Pharmaceutical is one of the largest drugmakers in the country, with a strong presence in generics and specialty medicines, and a growing footprint in global markets, including the U.S.
More Details and Deal Rationale
Reports suggested that Sun Pharmaceutical is in the final stages of a bid for Organon after more than three months of due diligence. The company is also working on a financing package, with support from banks like JPMorgan (JPM) and MUFG (MUFG), and could submit an offer in the coming weeks.
While Sun Pharma has called the reports speculative, the deal would make strategic sense. Organon’s strong portfolio in women’s health and established medicines could help Sun expand globally, especially in the U.S. It would also strengthen Sun’s position in branded generics and specialty drugs.
If completed, this would be the largest overseas acquisition by an Indian pharma company. However, Sun Pharma shares fell about 3% in Mumbai following the reports.
Is OGN a Good Stock to Buy?
Turning to Wall Street, analysts have a Moderate Sell consensus rating on OGN stock based on two Holds and three Sells assigned in the past three months. The average Organon stock price target of $9.33 per share implies a 5.36% upside potential.
